Seeking Alpha

Seattle Genetics (SGEN) is down 12.9% in spite of yesterday's Q3 beat, fueled by growing sales...

Seattle Genetics (SGEN) is down 12.9% in spite of yesterday's Q3 beat, fueled by growing sales of its Adcetris lymphoma drug. A 47% YTD gain could be driving investors to take profits, as could a downgrade to Neutral by Piper, which argues Adcetris' impact is fully baked in, and "broader approval" of the drug will take time.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs